{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-038061","form_type":"8-K","ticker":"GERN","cik":"0000886744","company_name":"GERON CORP","filed_at":"2023-08-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.884305+00:00","generated_at":"2026-06-12T10:34:42.655211+00:00","sec_items":["2.02","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Geron submits NDA for imetelstat in lower risk MDS; Q2 cash $400.2M","bullets":["Submitted first NDA for a telomerase inhibitor (imetelstat) to FDA for lower risk MDS in June 2023.","Cash, equivalents and securities of $400.2M as of June 30; expects to fund operations through end of 2025.","Reaffirmed FY2023 GAAP total expense guidance of $210M–$220M; non-GAAP $200M–$210M.","IMpactMF Phase 3 trial in myelofibrosis enrolled >40%; interim analysis expected H1 2025.","Appointed Scott Samuels as EVP, Chief Legal Officer and Corporate Secretary effective August 1, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-038061","json":"https://secwatch.observer/filing/0000950170-23-038061.json","markdown":"https://secwatch.observer/filing/0000950170-23-038061.md","text":"https://secwatch.observer/filing/0000950170-23-038061.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/886744/000095017023038061/0000950170-23-038061-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/886744/000095017023038061/gern-20230803.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T10:34:42.655211+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c8301805057d49a7337fab92d83474abb680a535","claim":"GERON CORP reported the three and six months ended June 30, 2023 results: revenue $29,000 and $50,000, respectively.","evidence_excerpt":"to fund its projected operating requirements through the end of 2025. Second Quarter 2023 Financial Results Revenues for the three and six months ended June 30, 2023, were $29,000 and $50,000, respectively, compared to $73,000 and $196,000 for the comparable 2022 periods. Revenues in both years primarily reflect estimated royalties from sales of cell-based","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/886744/000095017023038061/0000950170-23-038061-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the three and six months ended June 30, 2023"},{"label":"Revenue","value":"$29,000 and $50,000, respectively"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}